Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 19,992
- Reactions
- 27,496
This month's post for the yearly Comp @mullokintyre
last few months came to nought. Jumps around but mainly down -- shorts in control?
CU6 - Clarity Pharmaceuticals
- Thread starter System
- Start date
last few months came to nought. Jumps around but mainly down -- shorts in control?
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 19,992
- Reactions
- 27,496
This month's post for the yearly Comp @mullokintyre
Annual report out...
On the 28th of July, Clarity successfully completed a $203 million Placement with a small group of institutional investors who are close to the Company. The issue price of the Placement was $4.20 per share, which represented a 2.2% premium to Clarity’s previous closing price.
“The Placement has received phenomenal support, evidenced by the raising of over $200 million at not only a premium to the last closing share price, but a substantial premium to the share price observed for almost the entirety of CY2025. This places Clarity in a strong position where we can work to complete a number of high value-driving clinical trials, including our pivotal diagnostic Phase III trials, as we progress our products towards potential commercialisation,”
they're probably not too chuffed, losing 25% in the last 6 weeks
maybe the selling pressure is abating
Thorney Technologies (TEK) has 6 per cent of its portfolio in radiopharmaceutical business Clarity Pharmaceuticals..
Alex Waislitz has been liquidating parts of his share portfolio for weeks, with a looming divorce ,.... Thorney and various subsidiaries and related entities have sold down some holdings in many companies
Annual report out...
On the 28th of July, Clarity successfully completed a $203 million Placement with a small group of institutional investors who are close to the Company. The issue price of the Placement was $4.20 per share, which represented a 2.2% premium to Clarity’s previous closing price.
“The Placement has received phenomenal support, evidenced by the raising of over $200 million at not only a premium to the last closing share price, but a substantial premium to the share price observed for almost the entirety of CY2025. This places Clarity in a strong position where we can work to complete a number of high value-driving clinical trials, including our pivotal diagnostic Phase III trials, as we progress our products towards potential commercialisation,”
they're probably not too chuffed, losing 25% in the last 6 weeks
maybe the selling pressure is abating
Thorney Technologies (TEK) has 6 per cent of its portfolio in radiopharmaceutical business Clarity Pharmaceuticals..
Alex Waislitz has been liquidating parts of his share portfolio for weeks, with a looming divorce ,.... Thorney and various subsidiaries and related entities have sold down some holdings in many companies
Last edited:
